Co-receptor usage and HIV-1 intra-clade C polymorphisms in the protease and reverse transcriptase genes of HIV-1 isolates from Ethiopia and Botswana

Antiviral Therapy

Volumn 7, Issue 2, 2002, Pages 141-148

  Loemba, Hugues ^a   Brenner, Bluma ^a   Parniak, Michael A ^a   Ma'ayan, Shlomo ^d   Spira, Bonnie ^a   Moisi, Daniela ^a   Oliveira, Maureen ^a   Detorio, Mervi ^a   Essex, Max ^b,c   Wainberg, Mark A ^a  

^a MCGILL UNIVERSITY   (Canada)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c Botswana Harvard Laboratory   (Botswana)

^d HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; EFAVIRENZ; INDINAVIR; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 THIOPHENECARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; PALINAVIR; PROTEINASE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; THIOBENZIMIDAZOLE; UNCLASSIFIED DRUG; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

AMINO ACID SUBSTITUTION; ARTICLE; BOTSWANA; CLADISTICS; CLINICAL ARTICLE; ETHIOPIA; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIRUS GENE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN; COMPARATIVE STUDY; DRUG EFFECT; DRUG RESISTANCE; GENETICS; METABOLISM; MOLECULAR GENETICS; PHYLOGENY;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; BASE SEQUENCE; BOTSWANA; DRUG RESISTANCE; ETHIOPIA; HIV PROTEASE; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; RNA-DIRECTED DNA POLYMERASE;

EID: 0036592080     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Schinazi RF, Larder BA, & Mellors JW. Mutations in retroviral genes associated with drug resistance. International Antiviral News 1996; 4:95-107.
2. Telenti A, Nunoz M, Bleiber G, Ledergerber B & Kaufmann DD. Heterogeneity in the response to anti-retroviral therapy. AIDS Reviews 1999; 1:147-155.
3. Myers G, Korber B, & Hahn B. Human Retroviruses and AIDS 1995: A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos National Laboratory, Los Alamos. NM - Theoretical Biology and Biophysics Group, 1995.
4. Janssens W, Buve A & Nkengasong JN. The puzzle of HIV-1 subtypes in Africa. AIDS 1997; 11:705-712.
5. Essex M. State of the HIV pandemic. Journal of Human Virology 1998; 1:427-429.
6. Sato H, Tomita Y, Shibamura K, Shiino T, Miyakuni T & Takebe Y. Convergent evolution of reverse transcriptase (RT) genes of human immunodeficiency virus type 1 subtypes E and B following nucleoside analogue RT inhibitor therapies. Journal of Virology 2000; 74:5357-5362.
7. Quinones-Mateu ME, Albright JL, Mas A, Soriano V & Arts EJ. Analysis of pot gene heterogeneity, viral quasi-species, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. Journal of Virology 1998; 72:9002-9015.
8. Apetrei C, Descamps D, Collin G, Loussert-Ajaka I, Damond F, Duca M, Simon F & Brun-Vezinet E Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. Journal of Virology 1998; 72:3534.
9. Salomon H, Belmonte A, Nguyen K, Gu Z, Gelfand M & Wainberg MA. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. Journal of Clinical Microbiology 1994; 32:2000-2002.
10. Boulerice F, Bour S, Geleziunas R, Lvovitch A & Wainberg MA. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. Journal of Virology 1990; 64:1745-1755.
11. Delwart EL, Shpaer EG, McCutchan FE, Louwagie J, Grez M, Rubsamen-Waigmann H & Mullins JI. Genetic relationships determined by DNA heteroduplex mobility assay: analysis of HIV-1 env genes. Sciences 1993; 262:1257-1261.
12. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CAB, Schapiro JM & Dellamonica P. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-2199.
13. Abebe A, Demissie D, Goudsmit J, Brouwer M, Kuiken CL, Pollakis G, Schuitemaker H, Fontanet AL & Rinke de Wit TF. HIV-1 subtype C syncytium and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS 1999; 13:1305-1311.
14. Salminen MO, Johansson BO, Sonnerborg A, Ayehunie S, Gotte D, Leinikki P, Burke DS & McCutchan FE. Full-length sequence of Ethiopian Human Immunodeficiency Virus type 1 (HIV-1) isolate of genetic subtype C. AIDS Research and Human Retroviruses 1996; 12:1329-1339.
15. Ayenie S, Johansson BO, Salminen MO, Leinikki P, Sonnerborg A, Work-Zewdie D, Britton S & Strannegard O. HIV-1 in Ethiopia; Phylogenetic divergence from other HIV-1 strains. Virus Genes 1991; 5:359-366.
16. Abebe A, Lukashov VV, Pollakis, Kliphuis A, Fontanet AL, Goudsmit J & Rinke de Wit TF. Timing of the HIV-1 subtype C epidemic in Ethiopia based on early virus strains and subsequent virus diversification. AIDS 2001; 15:1555-1561.
17. Miguel EQ & Arts EJ. Recombination in HIV-1: Update and implications. AIDS Revues 1999; 1:89-100.
18. Bacheler L, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G & Abremski K. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrobial Agents and Chemotherapy 2000; 44:2475-2484.
19. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R & Rizzo C. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing non-nucleoside reverse transcriptase inhibitor therapy. Journal of Virology 2001; 75:4999-5008.
20. Grossman Z, Paxinos E, Maayan S, Shahar E, Mileguir F, Petropoulos C & Schapiro J. The development of protease inhibitor resistance in clade C HIV-1: Role of baseline drug susceptibility. The 1st IAS Conference on HIV Pathogenesis and treatment, Buenos Aires, Argentina, July 2001, Abstract 578.
21. Cane PA, de Ruiter A, Rice P, Wiselka M, Fox R & Pillay D. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. Journal of Clinical Microbiology 2001; 39:2652-2654.
22. Shafer RW, Eisen JA, Merigan TC & Katzenstein DA. Sequence and drug susceptibility of subtype C reverse transcriptase from Human Immunodeficiency Virus type 1 seroconverters in Zimbabwe. Journal of Virology 1997; 71:5441-5448.
23. Mital D & Pillay D. The impact of HIV-1 subtype on drug resistance. Journal of HIV Therapy 2001; 6:56-60.
24. Pillay D, Sinka K, Rice P, Peters B, Clarke J, Workman J, Evans B & Cane PA. Impact of HIV-1 subtype on NNRTI resistance mutations. Antiviral Therapy 2000; 5 (Supplement 3):128.
25. Peeters M, Vincent R, Perret JL, Lasky M, Patrel D, Liegeois F, Courgnaud V, Seng R, Matton T, Molinier S & Delaporte E. Evidence for differences in MT2 cell tropism according to genetic subtypes of HIV-1: syncytium-inducing variants seem rare among subtype C HIV-1 viruses. Journal of Acquired Immune Deficiency Syndrome and Human Retrovirology 1999; 20:115-121.
26. Ndung'u T, Renjifo B & Essex M. Construction and analysis of an infectious human immunodeficiency virus type 1 subtype C molecular clone. Journal of Virology 2001; 75:4964-4972.